Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

M3 Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

M3 şirketinin toplam hissedar öz sermayesi ¥373.9B ve toplam borcu ¥25.3B olup, bu da borç-öz sermaye oranını 6.8% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥506.5B ve ¥132.7B dir. M3 'in FAVÖK'ü ¥63.8B faiz karşılama oranı -45 dur. Şirketin ¥148.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

6.8%

Borç/özkaynak oranı

JP¥25.29b

Borç

Faiz karşılama oranı	-45x
Nakit	JP¥148.22b
Eşitlik	JP¥373.85b
Toplam yükümlülükler	JP¥132.65b
Toplam varlıklar	JP¥506.51b

Son finansal sağlık güncellemeleri

Is M3 (TSE:2413) Using Too Much Debt?

Jul 12

Recent updates

M3, Inc. (TSE:2413) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Oct 06

Return Trends At M3 (TSE:2413) Aren't Appealing

Sep 23

Some M3, Inc. (TSE:2413) Shareholders Look For Exit As Shares Take 26% Pounding

Aug 10

Results: M3, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Jul 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2413 'nin kısa vadeli varlıkları ( ¥239.7B ) kısa vadeli yükümlülüklerini ( ¥67.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: 2413 şirketinin kısa vadeli varlıkları ( ¥239.7B ) uzun vadeli yükümlülüklerini ( ¥65.0B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2413 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 2413 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 6.8% seviyesine yükseldi.

Borç Kapsamı: 2413 'nin borcu işletme nakit akışı ( 230.6% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 2413 ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.

M3 Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is M3 (TSE:2413) Using Too Much Debt?

Recent updates

Investor sentiment improves as stock rises 18%

M3, Inc. (TSE:2413) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Return Trends At M3 (TSE:2413) Aren't Appealing

Price target decreased by 7.2% to JP¥1,834

M3, Inc. to Report Q2, 2025 Results on Oct 30, 2024

Investor sentiment improves as stock rises 20%

Some M3, Inc. (TSE:2413) Shareholders Look For Exit As Shares Take 26% Pounding

Price target decreased by 7.2% to JP¥2,028

Investor sentiment deteriorates as stock falls 19%

Results: M3, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Estimating The Intrinsic Value Of M3, Inc. (TSE:2413)

Is M3 (TSE:2413) Using Too Much Debt?

Now 18% overvalued

Investor Optimism Abounds M3, Inc. (TSE:2413) But Growth Is Lacking

Price target decreased by 9.3% to JP¥2,215

Now 20% overvalued

New minor risk - Share price stability

M3, Inc. to Report Q1, 2025 Results on Jul 26, 2024

M3 (TSE:2413) Will Be Hoping To Turn Its Returns On Capital Around

Price target decreased by 7.4% to JP¥2,263

Full year 2024 earnings: EPS misses analyst expectations

M3, Inc., Annual General Meeting, Jun 26, 2024

Upcoming dividend of JP¥21.00 per share

M3's (TSE:2413) Dividend Will Be Increased To ¥21.00

Dividend increased to JP¥21.00

M3, Inc. to Report Fiscal Year 2024 Results on Apr 26, 2024

Is M3, Inc. (TSE:2413) Worth JP¥2.1k Based On Its Intrinsic Value?

Now 21% overvalued

Price target decreased by 7.9% to JP¥2,762

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

M3, Inc. to Report Q3, 2024 Results on Jan 31, 2024

Price target decreased by 8.7% to JP¥3,000

Price target decreased by 7.7% to JP¥3,158

M3, Inc. (TSE:2413) entered into a share tender agreement to acquire a 55% stake in Benefit One Inc. (TSE:2412) from Pasona Group Inc. (TSE:2168) and others for approximately ¥140 billion.

Price target decreased by 7.3% to JP¥3,241

Price target decreased by 7.1% to JP¥3,422

Second quarter 2024 earnings: EPS exceeds analyst expectations

M3, Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending March 31, 2024

M3, Inc. to Report Q2, 2024 Results on Oct 27, 2023

M3, Inc. (TSE:2413) acquired Messly Limited.

M3, Inc. (TSE:2413) acquired frogwell corporation.

M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

M3, Inc. to Report Q1, 2024 Results on Jul 28, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥19.00 per share at 0.5% yield

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

M3, Inc. (TSE:2413) acquired Michael Allen Company.

M3, Inc. to Report Q3, 2023 Results on Feb 03, 2023

No independent directors

Second quarter 2023 earnings released: EPS: JP¥18.38 (vs JP¥36.86 in 2Q 2022)

M3, Inc. (TSE:2413) acquired Rinkai Medical Service.

M3, Inc. to Report Q2, 2023 Results on Nov 02, 2022

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: JP¥19.87 (vs JP¥23.23 in 1Q 2022)

Investor sentiment improved over the past week

M3, Inc. (TSE:2413) acquired Edoctores Soluciones.

M3, Inc. to Report Q1, 2023 Results on Jul 27, 2022

Price target decreased to JP¥5,358

Full year 2022 earnings: EPS misses analyst expectations

M3, Inc. Announces Dividend for the Year Ended March 31, 2022, Payable on June 13, 2022

No independent directors

M3, Inc. to Report Q4, 2022 Results on Apr 27, 2022

Upcoming dividend of JP¥16.00 per share

Price target decreased to JP¥6,353

M3, Inc. Reaffirms Dividend Guidance For Year End March 31, 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

M3, Inc. (TSE:2413) acquired remaining stake in MirVracha LLC.

Price target decreased to JP¥6,953

M3, Inc. (TSE:2413) acquired 3H Holdings, 3H Medi Solution and 3H Clinical Trial.

Second quarter 2022 earnings released: EPS JP¥36.86 (vs JP¥12.15 in 2Q 2021)